LXRX
LEXICON PHARMACEUTICALS, INC.
$1.92
+1.59%
$852.9M
No data for this timeframe.
Vol
Market Cap$852.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders50 funds
Inst. Value$134.2M
Inst. Activity6 buys / 2 sells
Insider Activity4B / 0S
Insider Net $$369.7K
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases3
Recent Activity
Jun 12, 2026
SEC
A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & General Group doubling
INST-CLUSTER — Impact 5/10
Jun 11, 2026
SEC
A weak institutional cluster in LXRX shows 4 buyers (Schwab, Two Sigma, BofA, Morgan Stanley) adding $1.2M in aggregate
INST-CLUSTER — Impact 2/10
Jun 3, 2026
other
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmaco
Jun 3, 2026
Insider
DEBBANE RAYMOND acquired via exercise 89,312 shares
Director
Jun 3, 2026
Insider
BARKER SAM L acquired via exercise 89,312 shares
Director
Jun 3, 2026
Insider
Amouyal Philippe acquired via exercise 89,312 shares
Director
May 6, 2026
SEC
Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 million funded at clos
8-K — Impact 4/10
Inst.
Point72 Asset Management, L.P. — DOUBLED
7,814,606 shares ($12.2M)
Price Targets
$3.77
+96.4% upside
Strong Buy
Current $1.92
Low $1.75
Median $3.10
High $6.00
5 analysts
$1.75
$6.00
Analyst Ratings
3Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 | $-0.06 — $-0.03 | -602% YoY | 5 |
| Next Q | $-0.06 | $-0.07 — $-0.05 | -49% YoY | 5 |
| Current FY | $-0.16 | $-0.18 — $-0.14 | -13% YoY | 5 |
| Next FY | $-0.21 | $-0.27 — $-0.11 | -30% YoY | 5 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & General Group doubling
Jun 12, 2026
NEUTRAL
INST-CLUSTER
2/10
A weak institutional cluster in LXRX shows 4 buyers (Schwab, Two Sigma, BofA, Morgan Stanley) adding $1.2M in aggregate
Jun 11, 2026
MIXED
Press
6/10
Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Cardiology Annual Meeti
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $70.3M | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.8M | — |
| Point72 Asset Management, L.P. | $12.2M | DOUBLED |
| BlackRock, Inc. | $5.2M | — |
| MARSHALL WACE, LLP | $3.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND | M | $0.00 |
| Jun 3, 2026 | BARKER SAM | M | $0.00 |
| Jun 3, 2026 | Amouyal Philippe | M | $0.00 |
| Jun 3, 2026 | Cheung Ivan | M | $0.00 |
| Jun 3, 2026 | Sullivan Diane | M | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $134.2M total value (86,017,694 shares) as of 2026-Q1. Top holders: FMR, VANGUARD, Point72. Net buying activity: 6 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 45,056,338 | $70.3M | 52.4% | TRIM -33.5% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 9,519,167 | $14.8M | 11.1% | — |
| 3 | Point72 Asset Management, L.P. | 7,814,606 | $12.2M | 9.1% | DOUBLED +2651.4% |
| 4 | BlackRock, Inc. | 3,322,219 | $5.2M | 3.9% | — |
| 5 | MARSHALL WACE, LLP | 2,376,304 | $3.7M | 2.8% | ADD +88.2% |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,121,164 | $3.3M | 2.5% | — |
| 7 | CIBC Bancorp USA Inc. | 1,800,000 | $2.8M | 2.1% | — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1,600,500 | $2.5M | 1.9% | DOUBLED +508.0% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 1,332,284 | $2.1M | 1.5% | — |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,311,298 | $2.0M | 1.5% | ADD +29.6% |
| 11 | TWO SIGMA INVESTMENTS, LP | 1,199,632 | $1.9M | 1.4% | ADD +38.4% |
| 12 | CITADEL ADVISORS LLC | 1,094,901 | $1.7M | 1.3% | — |
| 13 | GOLDMAN SACHS GROUP INC | 1,070,517 | $1.7M | 1.2% | — |
| 14 | STATE STREET CORP | 964,038 | $1.5M | 1.1% | TRIM -68.6% |
| 15 | MACKENZIE FINANCIAL CORP | 772,677 | $1.2M | 0.9% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 560,700 | $874.7K | 0.7% | — |
| 17 | CITADEL ADVISORS LLC | 552,700 | $862.2K | 0.6% | — |
| 18 | VANGUARD PORTFOLIO MANAGEMENT LLC | 546,600 | $852.7K | 0.6% | — |
| 19 | BANK OF AMERICA CORP /DE/ | 526,103 | $820.7K | 0.6% | DOUBLED +415.3% |
| 20 | Invesco Ltd. | 512,426 | $799.4K | 0.6% | ADD +47.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | DOUBLED | 284,025 | 7,814,606 | +2651.4% | $12.2M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 1,262,367 | 2,376,304 | +88.2% | $3.7M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 263,254 | 1,600,500 | +508.0% | $2.5M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 102,097 | 526,103 | +415.3% | $820.7K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 100,532 | 152,616 | +51.8% | $238.1K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 273,800 | 106,800 | -61.0% | $166.6K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 268,433 | 37,430 | -86.1% | $58.4K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 11,735 | 15,450 | +31.7% | $24.1K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 57,804 | 102,097 | +76.6% | $117.4K | 2025-Q4 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 18,877 | 13,520 | -28.4% | $15.4K | 2025-Q4 |
| HRT FINANCIAL LP | DOUBLED | 46,447 | 117,549 | +153.1% | $135.00 | 2025-Q4 |
| CWM, LLC | TRIM | 26,744 | 13,179 | -50.7% | $15.00 | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 301 | 1 | -99.7% | $1.00 | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 883,227 | 1,144,632 | +29.6% | $1.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 403,922 | 559,008 | +38.4% | $754.7K | 2025-Q3 |
| GROUP ONE TRADING LLC | TRIM | 346,752 | 216,244 | -37.6% | $291.9K | 2025-Q3 |
| MORGAN STANLEY | ADD | 131,393 | 169,018 | +28.6% | $228.2K | 2025-Q3 |
| BANK OF MONTREAL /CAN/ | TRIM | 100,000 | 70,000 | -30.0% | $94.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 32,097 | 57,804 | +80.1% | $78.0K | 2025-Q3 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 74,454 | 18,877 | -74.6% | $28.7K | 2025-Q3 |
| CAPTRUST FINANCIAL ADVISORS | TRIM | 35,582 | 14,069 | -60.5% | $19.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 26,423 | 301 | -98.9% | $406.00 | 2025-Q3 |
| HRT FINANCIAL LP | NEAR_EXIT | 488,468 | 46,447 | -90.5% | $62.00 | 2025-Q3 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 90,864 | 35,738 | -60.7% | $48.00 | 2025-Q3 |
| CWM, LLC | NEAR_EXIT | 109,330 | 26,744 | -75.5% | $36.00 | 2025-Q3 |
16 unique insiders with 50 transactions. Net insider value: $369.7K ($369.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | BARKER SAM L | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Amouyal Philippe | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Cheung Ivan | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Sullivan Diane E. | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Swain Judith L | Director | EXERCISE | 89,312 | — | — |
| May 1, 2026 | DEBBANE RAYMOND | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | DEBBANE RAYMOND | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | Swain Judith L | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | Swain Judith L | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | Cheung Ivan | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | Cheung Ivan | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | BARKER SAM L | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | BARKER SAM L | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | SOBECKI CHRISTOPHER J | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | SOBECKI CHRISTOPHER J | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | Amouyal Philippe | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | Amouyal Philippe | Director | AWARD | 43,478 | — | — |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | EXERCISE | 408,434.7 | — | — |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | AWARD | 408,434.7 | — | — |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | EXERCISE | 20,421,735 | — | — |
| Feb 28, 2026 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | EXERCISE | 67,090 | — | — |
| Feb 28, 2026 | Gopinathan Suma | SVP, Discovery | EXERCISE | 14,000 | — | — |
| Feb 28, 2026 | Crum Brian T | SVP, General Counsel & Secr. | EXERCISE | 33,457 | — | — |
| Feb 28, 2026 | Exton Michael | Chief Executive Officer | EXERCISE | 503,263 | — | — |
| Feb 28, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | EXERCISE | 24,674 | — | — |
| Feb 28, 2026 | McDermott Wendy | SVP, Human Resources | EXERCISE | 27,697 | — | — |
| Feb 28, 2026 | Granowitz Craig B | SVP, Chief Medical Officer | EXERCISE | 35,790 | — | — |
| Feb 28, 2026 | Crum Brian T | SVP, General Counsel & Secr. | EXERCISE | 69,386 | — | — |
| Feb 28, 2026 | Coiante Scott M | SVP, Chief Financial Officer | EXERCISE | 160,237 | — | — |
| Feb 25, 2026 | DEBBANE RAYMOND | Director | BUY | 2,000 | $1.49 | $3.0K |
| Feb 23, 2026 | DEBBANE RAYMOND | Director | BUY | 100,000 | $1.47 | $147.0K |
| Feb 20, 2026 | DEBBANE RAYMOND | Director | BUY | 100,000 | $1.48 | $147.8K |
| Feb 19, 2026 | DEBBANE RAYMOND | Director | BUY | 50,000 | $1.44 | $72.0K |
| Feb 12, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | AWARD | 257,530 | — | — |
| Feb 12, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | AWARD | 386,300 | — | — |
| Feb 12, 2026 | Exton Michael | Chief Executive Officer | AWARD | 862,440 | — | — |
| Feb 12, 2026 | Exton Michael | Chief Executive Officer | AWARD | 1,293,670 | — | — |
| Feb 12, 2026 | Gopinathan Suma | SVP, Discovery | AWARD | 238,450 | — | — |
| Feb 12, 2026 | Gopinathan Suma | SVP, Discovery | AWARD | 357,680 | — | — |
| Feb 12, 2026 | Coiante Scott M | SVP, Chief Financial Officer | AWARD | 272,680 | — | — |
| Feb 12, 2026 | Coiante Scott M | SVP, Chief Financial Officer | AWARD | 409,020 | — | — |
| Feb 12, 2026 | Granowitz Craig B | SVP, Chief Medical Officer | AWARD | 346,610 | — | — |
| Feb 12, 2026 | Granowitz Craig B | SVP, Chief Medical Officer | AWARD | 519,920 | — | — |
| Feb 12, 2026 | Crum Brian T | SVP, General Counsel & Secr. | AWARD | 299,710 | — | — |
| Feb 12, 2026 | Crum Brian T | SVP, General Counsel & Secr. | AWARD | 449,560 | — | — |
| Feb 12, 2026 | McDermott Wendy | SVP, Human Resources | AWARD | 250,200 | — | — |
| Feb 12, 2026 | McDermott Wendy | SVP, Human Resources | AWARD | 375,300 | — | — |
| Feb 12, 2026 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | AWARD | 193,740 | — | — |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 4.1/10.
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & Ge
Jun 12, 2026
NEUTRAL
INST-CLUSTER
2/10
A weak institutional cluster in LXRX shows 4 buyers (Schwab, Two Sigma, BofA, Morgan Stanley) adding
Jun 11, 2026
NEUTRAL
8-K
4/10
Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 mi
May 6, 2026
BEARISH
8-K
6/10
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
2/10
Lexicon Pharmaceuticals announced it will release Q1 2026 financial results on May 7, 2026. The fili
Apr 30, 2026
NEUTRAL
DEFA14A
3/10
Lexicon Pharmaceuticals, Inc. has filed a definitive additional materials proxy statement (DEFA14A)
Mar 16, 2026
BULLISH
8-K
7/10
Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by l
Mar 5, 2026
MIXED
6/10
Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Car
Mar 24, 2026
BULLISH
7/10
Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX985
Mar 23, 2026
MIXED
6/10
Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial results with significantly reduced
Mar 5, 2026
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 3 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.77 mean target
+96.4% upside
Strong Buy (2.00)
$1.75 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $1.92 |
| Target Low | $1.75 |
| Target Mean | $3.77 |
| Target Median | $3.10 |
| Target High | $6.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.03 | -602.3% | +0.0% | — | $0.0B | -86.2% | 5 |
| Next Q 2026-09-30 |
$-0.06 | $-0.07 | $-0.05 | -48.9% | +0.0% | — | $0.0B | -78.3% | 5 |
| Current FY 2026-12-31 |
$-0.16 | $-0.18 | $-0.14 | -13.3% | +0.0% | 2↑ 0↓ | $0.0B | -23.4% | 5 |
| Next FY 2027-12-31 |
$-0.21 | $-0.27 | $-0.11 | -30.0% | +0.0% | 0↑ 1↓ | $0.0B | -47.2% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.050 | |
| 30d ago | $-0.050 | |
| 60d ago | $-0.055 | +0.005 |
| 90d ago | $-0.055 | +0.005 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
LXRX set to spike
▲ 1
💬 0
⚡ 0.0
Jun 3, 2026
other
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function grou
May 28, 2026
other
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
<p align="left">THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Jg-AJURJmAVl73VhxWU7Kgpw_
May 7, 2026
earnings
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
<p align="center"><strong><em>SONATA-HCM anticipated to be fully enrolled mid-2026 </em></strong></p>
May 7, 2026
earnings_calendar
LXRX Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
short_volume
Short Volume: LXRX — 59.3% short (0.4M / 0.7M)
Short: 387,102 | Exempt: 0 | TRF Vol: 652,750 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
<p align="left">THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company wi
Apr 30, 2026
earnings_calendar
LXRX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 22, 2026
Enforcement
HSR Early Termination: Stichting Administratiekantoor Westend; Lexicon Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Stichting Administratiekantoor Westend; Lexicon Pharmaceut
Apr 17, 2026
routine
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
<p align="center"><em> Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optima
Apr 6, 2026
short_volume
Short Volume: LXRX — 63.0% short (0.5M / 0.8M)
Short: 481,359 | Exempt: 1 | TRF Vol: 764,472 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: LXRX — 71.1% short (0.9M / 1.2M)
Short: 851,241 | Exempt: 30 | TRF Vol: 1,196,609 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
fda
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sot
Mar 23, 2026
fda
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
<p align="center"><em>LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associa
Mar 5, 2026
earnings
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
<p align="center"><strong><em>Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM
Mar 5, 2026
earnings_calendar
LXRX Q4 2025 Earnings After Market Close — 2026-03-05
Mar 3, 2026
other
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
<p align="left">THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company m